Pfizer (NYSE:PFE) Trading Up 1.3% – Should You Buy?

Pfizer Inc. (NYSE:PFE) traded up 1.3% during trading on Tuesday . The company traded as high as $25.96 and last traded at $25.6640. 40,929,096 shares changed hands during trading, a decline of 3% from the average session volume of 42,348,012 shares. The stock had previously closed at $25.33.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer launched a new Phase 3 endometrial cancer trial, a sign the company is still advancing its oncology pipeline and trying to compete more directly with larger cancer drug players like Merck. Pfizer Takes Aim at Merck in New Phase 3 Endometrial Cancer Trial
• Positive Sentiment: Several recent commentary pieces argue Pfizer remains undervalued, with analysts and market-watch articles pointing to its relatively low valuation and stable balance sheet as reasons investors may be willing to buy the stock. Why Pfizer Stock Still Looks Deeply Undervalued In 2026
• Neutral Sentiment: Pfizer is also getting attention from general stock screens and “under $30” lists, which tends to keep it on investors’ radar but does not represent a direct business catalyst. The SoFi CEO Just Bought 70000 Shares With His Own Money Here Are Four More Under 30 Worth a Closer Look
• Neutral Sentiment: Analyst sentiment remains cautious, with Pfizer receiving a consensus “Hold” rating, suggesting Wall Street sees limited near-term upside despite the company’s defensive profile. Pfizer Inc Receives Consensus Recommendation of Hold from Analysts
• Negative Sentiment: Pharma stocks, including Pfizer, were recently pressured by news that TrumpRx may see a “dramatic expansion,” reviving investor worries about drug pricing pressure and margins across the sector. PFE NVO LLY Pharma Stocks Drop on News TrumpRx Set for Dramatic Expansion

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. CICC Research assumed coverage on shares of Pfizer in a research note on Thursday, April 16th. They set an “outperform” rating and a $33.00 price objective on the stock. Zacks Research upgraded shares of Pfizer from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. Bank of America lowered their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Thursday, April 9th. Wall Street Zen upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Finally, Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $28.84.

Pfizer Stock Performance

The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The stock has a market cap of $146.27 billion, a price-to-earnings ratio of 19.59 and a beta of 0.35. The company’s 50-day simple moving average is $26.96 and its 200-day simple moving average is $26.20.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. The firm had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts predict that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.7%. The ex-dividend date is Friday, May 8th. Pfizer’s payout ratio is presently 131.30%.

Hedge Funds Weigh In On Pfizer

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Orographic Financial Advisors LLC purchased a new position in Pfizer during the 1st quarter worth approximately $2,145,000. Royal Fund Management LLC grew its position in Pfizer by 275.6% during the 1st quarter. Royal Fund Management LLC now owns 80,508 shares of the biopharmaceutical company’s stock worth $2,261,000 after purchasing an additional 59,072 shares in the last quarter. Edgestream Partners L.P. grew its position in Pfizer by 46.5% during the 1st quarter. Edgestream Partners L.P. now owns 198,509 shares of the biopharmaceutical company’s stock worth $5,574,000 after purchasing an additional 63,019 shares in the last quarter. Kentucky Retirement Systems grew its position in Pfizer by 50.0% during the 1st quarter. Kentucky Retirement Systems now owns 535,087 shares of the biopharmaceutical company’s stock worth $16,390,000 after purchasing an additional 178,402 shares in the last quarter. Finally, Bull Harbor Capital LLC acquired a new stake in shares of Pfizer during the 1st quarter valued at $464,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.